|1||NCT01464606||Active, not recruiting||International Pleuropulmonary Blastoma (PPB) Treatment and Biology Registry||
||156||All||up to 21 Years (Child, Adult)||NCT01464606||PPB Reg Tx-Biol-001||December 22, 2009||December 2021||December 2021||November 3, 2011||May 20, 2019||
|2||NCT02452554||Active, not recruiting||Lorvotuzumab Mertansine in Treating Younger Patients With Relapsed or Refractory Wilms Tumor, Rhabdomyosarcoma, Neuroblastoma, Pleuropulmonary Blastoma, Malignant Peripheral Nerve Sheath Tumor, or Synovial Sarcoma||
||Other / NIH||
||62||All||12 Months to 30 Years (Child, Adult)||NCT02452554||ADVL1522
|October 12, 2015||June 30, 2017||May 22, 2015||June 28, 2019||
† Study has passed its completion date and status has not been verified in more than two years.